P H Thaker1, R Salani2, W E Brady3, H A Lankes3, D E Cohn2, D G Mutch1, R S Mannel4, K M Bell-McGuinn5, P A Di Silvestro6, D Jelovac7, J S Carter8, W Duan9, K E Resnick10, D S Dizon11, C Aghajanian5, P M Fracasso12. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Siteman Cancer Center, Washington University School of Medicine, St. Louis. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University School of Medicine, Columbus, USA. 3. NRG/Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, USA. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, USA. 5. Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA. 6. Department of Obstetrics and Gynecology, Women & Infants Hospital, Providence, USA. 7. Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA. 8. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, USA. 9. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA. 10. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University School of Medicine, Cleveland, USA. 11. Division of Medical Gynecologic Oncology, Massachusetts General Hospital Cancer Center, Boston, USA. 12. Division of Hematology/Oncology, Department of Medicine, University of Virginia, Charlottesville, USA.
Abstract
Background: Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects of cisplatin. Given the use of cisplatin and paclitaxel as first-line treatment for persistent or recurrent cervical cancer, we aimed to estimate the maximum tolerated dose (MTD) of the PARP inhibitor veliparib when added to chemotherapy. Patients and methods: Women with persistent or recurrent cervical carcinoma not amenable to curative therapy were enrolled. Patients had to have received concurrent chemotherapy and radiation as well as possible consolidation chemotherapy; have adequate organ function. The trial utilized a standard 3 + 3 phase I dose escalation with patients receiving paclitaxel 175 mg/m2 on day 1, cisplatin 50 mg/m2 on day 2, and escalating doses of veliparib ranging from 50 to 400 mg orally two times daily on days 1-7. Cycles occurred every 21 days until progression. Dose-limiting toxicities (DLTs) were assessed at first cycle. Fanconi anemia complementation group D2 (FANCD2) foci was evaluated in tissue specimens as a biomarker of response. Results: Thirty-four patients received treatment. DLTs (n = 1) were a grade 4 dyspnea, a grade 3 neutropenia lasting ≥3 weeks, and febrile neutropenia. At 400 mg dose level (DL), one of the six patients had a DLT, so the MTD was not reached. Across DLs, the objective response rate (RR) for 29 patients with measurable disease was 34% [95% confidence interval (CI), 20%-53%]; at 400 mg DL, the RR was 60% (n = 3/5; 95% CI, 23%-88%). Median progression-free survival was 6.2 months (95% CI, 2.9-10.1), and overall survival was 14.5 months (95% CI, 8.2-19.4). FANCD2 foci was negative or heterogeneous in 31% of patients and present in 69%. Objective RR were not associated with FANCD2 foci (P = 0.53). Conclusions: Combining veliparib with paclitaxel and cisplatin as first-line treatment for persistent or recurrent cervical cancer patients is safe and feasible. Clinical trial information: NCT01281852.
Background: Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects of cisplatin. Given the use of cisplatin and paclitaxel as first-line treatment for persistent or recurrent cervical cancer, we aimed to estimate the maximum tolerated dose (MTD) of the PARP inhibitor veliparib when added to chemotherapy. Patients and methods: Women with persistent or recurrent cervical carcinoma not amenable to curative therapy were enrolled. Patients had to have received concurrent chemotherapy and radiation as well as possible consolidation chemotherapy; have adequate organ function. The trial utilized a standard 3 + 3 phase I dose escalation with patients receiving paclitaxel 175 mg/m2 on day 1, cisplatin 50 mg/m2 on day 2, and escalating doses of veliparib ranging from 50 to 400 mg orally two times daily on days 1-7. Cycles occurred every 21 days until progression. Dose-limiting toxicities (DLTs) were assessed at first cycle. Fanconi anemia complementation group D2 (FANCD2) foci was evaluated in tissue specimens as a biomarker of response. Results: Thirty-four patients received treatment. DLTs (n = 1) were a grade 4 dyspnea, a grade 3 neutropenia lasting ≥3 weeks, and febrile neutropenia. At 400 mg dose level (DL), one of the six patients had a DLT, so the MTD was not reached. Across DLs, the objective response rate (RR) for 29 patients with measurable disease was 34% [95% confidence interval (CI), 20%-53%]; at 400 mg DL, the RR was 60% (n = 3/5; 95% CI, 23%-88%). Median progression-free survival was 6.2 months (95% CI, 2.9-10.1), and overall survival was 14.5 months (95% CI, 8.2-19.4). FANCD2 foci was negative or heterogeneous in 31% of patients and present in 69%. Objective RR were not associated with FANCD2 foci (P = 0.53). Conclusions: Combining veliparib with paclitaxel and cisplatin as first-line treatment for persistent or recurrent cervical cancerpatients is safe and feasible. Clinical trial information: NCT01281852.
Authors: David Cella; Helen Q Huang; Bradley J Monk; Lari Wenzel; Jo Benda; D Scott McMeekin; David Cohn; Lois Ramondetta; Cecelia H Boardman Journal: Gynecol Oncol Date: 2010-09-15 Impact factor: 5.482
Authors: Charles Kunos; Wei Deng; Dawn Dawson; Jayanthi S Lea; Kristine M Zanotti; Heidi J Gray; David P Bender; Perry P Guaglianone; Jori S Carter; Kathleen N Moore Journal: Int J Gynecol Cancer Date: 2015-03 Impact factor: 3.437
Authors: Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Toshiyasu Taniguchi; Marc Tischkowitz; Najim Ameziane; Shirley V Hodgson; Christopher G Mathew; Hans Joenje; Samuel C Mok; Alan D D'Andrea Journal: Nat Med Date: 2003-04-07 Impact factor: 53.440
Authors: Eve T Rodler; Brenda F Kurland; Melissa Griffin; Julie R Gralow; Peggy Porter; Rosa F Yeh; Vijayakrishna K Gadi; Jamie Guenthoer; Jan H Beumer; Larissa Korde; Sandra Strychor; Brian F Kiesel; Hannah M Linden; John A Thompson; Elizabeth Swisher; Xiaoyu Chai; Stacie Shepherd; Vincent Giranda; Jennifer M Specht Journal: Clin Cancer Res Date: 2016-01-22 Impact factor: 12.531
Authors: Matthew M Harkenrider; Merry Jennifer Markham; Don S Dizon; Anuja Jhingran; Ritu Salani; Ramy K Serour; Jean Lynn; Elise C Kohn Journal: J Natl Cancer Inst Date: 2020-11-01 Impact factor: 13.506
Authors: Karen A Cadoo; Rachel N Grisham; Roisin E O'Cearbhaill; Nicole N Boucicaut; Melissa Henson; Alexia Iasonos; Qin Zhou; Debra M Sarasohn; Jacqueline Gallagher; Sara Kravetz; Dmitriy Zamarin; Vicky Makker; Paul J Sabbatini; William P Tew; Carol Aghajanian; Jason A Konner Journal: Gynecol Oncol Date: 2020-01-17 Impact factor: 5.482
Authors: Michael J Jelinek; Nathan R Foster; Alex J Zoroufy; Gary K Schwartz; Pamela N Munster; Tanguy Y Seiwert; Jonas A de Souza; Everett E Vokes Journal: Oral Oncol Date: 2021-01-26 Impact factor: 5.337